JP2025510642A - 標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物 - Google Patents

標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物 Download PDF

Info

Publication number
JP2025510642A
JP2025510642A JP2024555049A JP2024555049A JP2025510642A JP 2025510642 A JP2025510642 A JP 2025510642A JP 2024555049 A JP2024555049 A JP 2024555049A JP 2024555049 A JP2024555049 A JP 2024555049A JP 2025510642 A JP2025510642 A JP 2025510642A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510642A5 (https=
Inventor
ラインハルト ツァイドラー
カトリーン ゲルトナー
Original Assignee
ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー
エクシミウム バイオテクノロジーズ ゲーエムベーハー
クリニクム デア ウニヴェルズィテート ミュンヒェン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー, エクシミウム バイオテクノロジーズ ゲーエムベーハー, クリニクム デア ウニヴェルズィテート ミュンヒェン filed Critical ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー
Publication of JP2025510642A publication Critical patent/JP2025510642A/ja
Publication of JP2025510642A5 publication Critical patent/JP2025510642A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024555049A 2022-03-14 2023-03-14 標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物 Pending JP2025510642A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22161839.0 2022-03-14
EP22161839 2022-03-14
PCT/EP2023/056397 WO2023174897A1 (en) 2022-03-14 2023-03-14 Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell

Publications (2)

Publication Number Publication Date
JP2025510642A true JP2025510642A (ja) 2025-04-15
JP2025510642A5 JP2025510642A5 (https=) 2026-03-25

Family

ID=80738871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555049A Pending JP2025510642A (ja) 2022-03-14 2023-03-14 標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物

Country Status (6)

Country Link
EP (1) EP4493587A1 (https=)
JP (1) JP2025510642A (https=)
KR (1) KR20250099050A (https=)
CN (1) CN119156400A (https=)
CA (1) CA3245743A1 (https=)
WO (1) WO2023174897A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025255706A1 (en) * 2024-06-11 2025-12-18 Zeno Therapeutics Pte. Ltd. Diagnosis and treatment of aml
WO2025054760A1 (en) * 2023-09-11 2025-03-20 Zeno Therapeutics (Shenzhen) Co. Ltd. Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025056603A1 (en) * 2023-09-11 2025-03-20 Eximmium Biotechnologies Gmbh Srrm2 binders for treating and diagnosing blood cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR

Also Published As

Publication number Publication date
CA3245743A1 (en) 2023-09-21
WO2023174897A1 (en) 2023-09-21
EP4493587A1 (en) 2025-01-22
CN119156400A (zh) 2024-12-17
KR20250099050A (ko) 2025-07-01

Similar Documents

Publication Publication Date Title
JP7455787B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
EP2096122B1 (en) Anti-human dlk-1 antibody showing anti-tumor activity in vivo
EP2900695B1 (en) Mesothelin antibodies and methods for eliciting potent antitumor activity
JP2025510642A (ja) 標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物
EP2275537B1 (en) Anti-human dlk-1 antibody having anti-tumor activity in vivo
US12049500B2 (en) Anti-nectin-4-antibodies and uses thereof
JP7024072B2 (ja) 抗ｃｄ３抗体およびそれを含む癌処置用医薬組成物
CN104520331A (zh) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
IL224969A (en) Modulators and methods of use
TW202402805A (zh) 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
US7396915B2 (en) Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
US9273140B2 (en) Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
US20240050475A1 (en) Composition comprising an antibody which binds to human prdx4 present on the cell surface of a target cell
AU2016329409B2 (en) Compositions and methods for inhibiting cancer stem cells
WO2025054760A1 (en) Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025125557A1 (en) Composition comprising an antibody which binds to human igf2bp1 present on the cell surface of a target cell
WO2025255706A1 (en) Diagnosis and treatment of aml
CN116981688A (zh) 包含结合存在于靶细胞的细胞表面上的人prdx4的抗体的组合物
AU2024340551A1 (en) Srrm2 binders for treating and diagnosing blood cancer
EA049994B1 (ru) Конъюгаты антитела против нектина-4 и эксатекана
NZ744187B2 (en) Therapeutic anti-cd9 antibody
HK1213000B (en) Mesothelin antibodies and methods for eliciting potent antitumor activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313